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Due to the myriad interactions between prosurvival and proapoptotic members of the Bcl-2 family of proteins,
establishing the mechanisms that regulate the intrinsic apoptotic pathway has proven challenging. Mechanistic in-
sights have primarily been gleaned from in vitro studies because genetic approaches in mammals that produce un-
ambiguousdataaredifficult todesign.Herewedescribeamutation inmouseandhumanBakthat specificallydisrupts
its interaction with the prosurvival protein Bcl-xL. Substitution of Glu75 in mBak (hBAK Q77) for leucine does not
affect the three-dimensional structure of Bak or killing activity but reduces its affinity for Bcl-xL via loss of a single
hydrogenbond.Using thismutant,we investigated the requirement forphysical restraintofBakbyBcl-xL inapoptotic
regulation. Invitro,BakQ75L cellswere significantlymore sensitive tovarious apoptotic stimuli. In vivo, loss ofBcl-xL
binding to Bak led to significant defects in T-cell and blood platelet survival. Thus, we provide the first definitive in
vivo evidence that prosurvival proteins maintain cellular viability by interacting with and inhibiting Bak.
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The Bcl-2 family of proteins determines cell fate by regu-
lating the integrity of the mitochondrial outer membrane
(MOM). It comprises three subgroups. The first includes
the prosurvival proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and
BFL-1/A1), which prevent apoptosis by inhibiting the acti-
vation of a second group consisting of Bax and Bak (and
possibly Bok). The latter represents the essential media-
tors of the pathway. Upon activation, they oligomerize
and form pore-like structures in the MOM. The third
group contains the BH3-only proteins (e.g., Bim, Bid,
Puma, and Noxa), which lie upstream and are responsible
for the initiation of apoptosis.
Two alternative mechanisms have been proposed for
how apoptosis is regulated by prosurvival proteins. One
of these (“mode 1”) proposes that Bcl-2 and other prosur-
vival proteins sequester a subset of BH3-only proteins—
the so-called “activators” (e.g., Bim and Bid)—that can
directly engage and activate Bax and Bak (Cheng et al.
2001; Letai et al. 2002; Kuwana et al. 2005; Llambi et al.
2011). Here, proapoptotic signals lead to displacement of
the activators by competitive interactions with “sensitiz-
er” BH3-only proteins (e.g., Bad), thereby allowing Bax/
Bak oligomerization and consequent MOM damage. In
the second mechanism (“mode 2”), prosurvival proteins
physically engage “activated” Bax/Bak to prevent their
oligomerization and pore formation (Willis et al. 2005,
2007; Fletcher et al. 2008; Llambi et al. 2011). Apoptosis
occurs when BH3-only proteins disrupt this interaction
and unleash Bak and Bax. While there was some contro-
versy over which of these mechanisms best describes
how apoptosis is regulated, evidence from various ex-
perimental approaches suggests that both contribute to
apoptotic control (the “unified,” “interconnected hierar-
chical,” and “embedded together” models) (Leber et al.
2010; Llambi et al. 2011; Chen et al. 2015).
Although the studies that uncovered thesemechanisms
provide persuasive insights into how cell death is regulat-
ed, they are all essentially based on in vitro evidence, as it
has proven very difficult to generate conclusive data in
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vivo. For example, despite the range of profound cell and
organ defects provoked by genetic deletion of one or
more prosurvival proteins in mice, it is impossible to dis-
tinguish whether these phenotypes reflect a role for mode
1 and/or mode 2 regulation (Youle and Strasser 2008).
Nevertheless, studies using BH3-only protein chimeric
knock-in or quadruple BH3-only protein knockout mice
have provided some evidence for physiological roles of
mode 1 regulation and ex vivo evidence for mode 2 (Meri-
no et al. 2009; Chen et al. 2015). Here, we describe the first
mouse model to provide evidence for physiological roles
for mode 2 regulation in vivo.
Results
Mutations in the BAK BH3 domain that specifically
disrupt BCL-XL binding
In considering the mode 2 mechanism of apoptotic con-
trol, we hypothesized that specific mutations could be in-
troduced into Bax or Bak that would disrupt binding to
prosurvival Bcl-2 proteins without influencing any poten-
tial mode 1 interactions (Fig. 1A). We reasoned that Bak
would bemore tractable than Bax, as it is regulated by few-
er prosurvival proteins and does not require translocation
to theMOM to function (Willis et al. 2005, 2007; Fletcher
et al. 2008; Llambi et al. 2011). Mode 2 regulation of Bak is
mediated by its BH3 domain (Willis et al. 2005; Chen et al.
2015), which is also critical for Bak homodimerization and
proapoptotic activity (Dewson et al. 2008). Hence, we set
out to identify Bak BH3 domainmutations that influenced
interactions with its key prosurvival protein regulators,
Mcl-1 and Bcl-xL (Willis et al. 2005; Chen et al. 2015),
but did not influence assembly into the higher-order Bak
oligomers required to mediate MOM damage.
First, we performed alanine-scanning mutagenesis of
the human BAK BH3 domain as previously described
(Lee et al. 2008). As expected, the conserved residues
that define BH3 domains (i.e., V74, L78, I81, D83, and
I85 and small residuesG75 andG82) weremost important
for prosurvival protein binding. Individual substitution of
each to alanine significantly reduced the affinity of hBAK
for BCL-XL and MCL-1 (Fig. 1B–E). Furthermore, these
mutants of full-length BAK failed to homodimerize to a
significant degree in response to tBID treatment (Fig. 1F)
and, consequently, to killBax−/−/Bak−/−mouse embryon-
ic fibroblasts (MEFs) reconstituted with them (Fig. 1G). In
contrast, the R76A and Q77Amutants, which exhibited a
fourfold to eightfold reduction in binding to BCL-XL (Fig.
1B,D), dimerized more efficiently in response to tBID
and killed Bax−/−/Bak−/− MEFs. These data suggest that
the hBAK R76A and Q77A mutations specifically disrupt
mode 2 interactions with BCL-XL but do not affect the
ability of BAK to homodimerize and mediate cell death.
A mouse model of mode 2 prosurvival function
In parallel with our biochemical studies, we performed an
N-ethyl-N-nitrosourea (ENU) mutagenesis screen in mice
and identified a missense point mutation in Bak that, re-
markably, was predicted to encode a leucine substitution
at residue Glu75 (Q75L), equivalent to Q77L in hBAK.We
therefore examined whether the mBak Q75L mutation
also influenced prosurvival protein binding. An mBak
Q75L BH3 synthetic peptide boundmBcl-xL approximate-
ly sevenfold weaker than the wild-type Bak BH3 (Fig. 2A),
an effect very similar to that of the hBAK BH3 Q77A mu-
tation (Fig. 1B,D). Binding toMcl-1, Bcl-w, and A1was un-
affected, while the affinity for Bcl-2 was 2.5-fold weaker
than wild-type mBak BH3. Consistent with these data,
in coimmunoprecipitation experiments usingmouse liver
mitochondria (MLM) purified from wild-type, Bak+/Q75L,
or BakQ75L/Q75L mice, Mcl-1 associated nearly equally
with full-length Bak or BakQ75L (Fig. 2B). Furthermore,
Bcl-xL coimmunoprecipitated only with wild-type Bak
present in Bak+/+ and Bak+/Q75L MLM but not with
BakQ75L from the homozygous BakQ75L/Q75L MLM (Fig.
2B). TheQ75Lmutation did not affect Bak homodimeriza-
tion following tBID activation, and its association with
VDAC2, a negative regulator of Bak (Cheng et al. 2003;
Lazarou et al. 2010), was also unimpaired (Fig. 2C). Hence,
the BakQ75L mouse represents an in vivo reporter for the
interaction between Bak and Bcl-xL.
Structural basis for the reduced affinity of BakQ75L
for BCL-XL
We next examined the effect of the BakQ75L mutation on
the protein’s global structure and interaction with Bcl-xL.
We focused on hBAKQ77L to enable comparison with pub-
lished hBAK structures. BAKQ77L adopted a three-dimen-
sional structure essentially identical to that of wild-type
hBAK (root mean square deviation [RMSD] 0.187 Å),
with the L77 side chain positioned similarly to that of
the wild-type Q77 residue (Fig. 2D; Supplemental Table
S1). Hence, the Q77L mutation does not cause significant
structural changes inBAK.Wealso solved the structuresof
the wild-type and mutant BAK BH3:BCL-XL complexes
(Supplemental Table S1). Both BH3 domains (human
wild-type BAKandmousemutant Bak) engaged the hydro-
phobic BH3 domain-binding groove of BCL-XL in the ca-
nonical manner (Fig. 2E). Two residues on BCL-XL (Y101
and Q111) potentially hydrogen-bond to Q77 in hBAK
BH3 (Fig. 2F), and this bond is absent when Q77 is substi-
tuted for leucine (Fig. 2G). To determine whether the
loss of affinity for BCL-XL is due to disruption of these in-
teractions, we generated Y101F, Q111A, and Y101F/
Q111A mutants of mBcl-xL. Both the Y101F and the
Y101F/Q111A mutants bound to wild-type mBak BH3
∼3.5-fold more weakly than to wild-type BCL-XL, while
the Q111A mutation had no impact (data not shown).
Hence, the disruptive effect of the BakQ75L mutation on
binding to Bcl-xL is likely attributed to the loss of a hydro-
gen bond between Bak Q75 and Bcl-xL Y101.
The BakQ75L mutation renders cells more sensitive
to proapoptotic agents
Given that only the Bak:Bcl-xL interaction was signifi-
cantly impaired in BakQ75L mice, they provided an ideal
Bcl-xL directly inhibits Bak in vivo
GENES & DEVELOPMENT 1241
 Cold Spring Harbor Laboratory Press on March 15, 2020 - Published by genesdev.cshlp.orgDownloaded from 
system to probe the requirement for prosurvival protein
inhibition bymode 2 both in vitro and in vivo.We first ex-
amined MEFs from BakQ75L embryos. As wild-type MEFs
are dependent on both Mcl-1 and Bcl-xL for their survival
(Willis et al. 2005; Chen et al. 2015), we hypothesized that
MEFs derived from BakQ75L embryos would be primarily
dependent on Mcl-1. Consistent with this, Bak+/Q75L
and BakQ75L/Q75L MEFs died following expression of
the MCL-1-selective BH3-only protein NOXA, as did
Bcl-x−/− MEFs (Fig. 3A). In contrast, NOXA expression
did not affect wild-typeMEF survival. We therefore tested
other proapoptotic stimuli. Approximately fourfold less of
the tBID variant M97A that fails to bind BCL-XL
(Supplemental Fig. S1A) was required to induce cyto-
chrome c release in BakQ75L/Q75L MEFs relative to wild-
typecells (1.1nMvs.4.5nM)(Fig.3B).Accordingly, fourfold
more recombinant BCL-XL (25 nM vs. 6.3 nM) was re-
quired to prevent cytochrome c release in BakQ75L/Q75L
Figure 1. A BAK BH3mutation that affects BCL-XL binding but not BAK function. (A) Schematic of mode 1 and mode 2 mechanisms of
apoptosis regulation. (B,C ) To investigate the contribution of each residue within the BAK BH3 domain for binding either BCL-XL (B) or
MCL-1 (C ), each residue of a phage-displayed BAK BH3 peptidewasmutated to alanine (except for native alanines or glycines, whichwere
replaced with glutamic acid), and their relative affinities (IC50) were determined by solution competition ELISA. The data represent the
fold-reduction in binding of the mutant sequence compared with wild-type BAK BH3. The upper limit on the Y-axes was set to >30-fold
reduction based on the IC50 (>10 μM) of a nonbindingmutant (G82E) independently confirmed in competition binding assays using surface
plasmon resonance. (D,E) Representative binding curves for wild-type BAK BH3 and mutants in competition binding assays with BCL-xL
(D) and MCL-1 (E). Mutants such as L78A and I85A show significantly reduced binding to both BCL-xL (D) and MCL-1 (E), while BAK
Q77A impacts (eightfold reduction) only on BCL-XL binding. (F ) BAK BH3 mutations except R76A and Q77A impair the ability of BAK
to homodimerize. Permeabilized Bax−/−/Bak−/− mouse embryonic fibroblasts (MEFs) expressing BAK BH3 mutants were treated with
tBID, and BAK dimerization was assessed by BN PAGE and Western blotting. Note that BAK G75E did not express at levels detectable
by Western blotting. The blot was probed with anti-BAK antibody. (G) Mutation of key residues involved in prosurvival protein binding
rendered BAK inactive, except R76A and Q77A. Bax−/−/Bak−/− MEFs expressing BAK BH3mutants were transduced with a retrovirus to
express either BIMS or the inert mutant BIMS4E, and colony numbers were determined after 7 d. Viability is the number of colonies in the
BIMS-expressing cells relative to those expressing BIMS4E. Data are presented as mean ± SD of n = 3 experiments in B, C, and G.
Lee et al.
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MEFs compared with wild-type cells following treatment
with tBIDM97A (Fig. 3C). Furthermore, Bak+/Q75L and
BakQ75L/Q75 MEFs were significantly more sensitive
thanwild-type cells to drug-induced apoptosis in response
to bortezomib, actinomycin D, cycloheximide, and etopo-
side (Fig. 3D–G). Inmost cases BakQ75LMEFswere as sen-
sitive as cells deficient in Bcl-xL (where inhibition of both
mode 1 and mode 2 by Bcl-xL is absent). Bak levels are es-
sentially the same in all cell lines; hence, this should not
have influenced the outcome in these experiments
(Supplemental Fig. S1B). These data indicate that the
BakQ75Lmutation reduces the capacity of Bcl-xL to inhibit
Bak’s killing activity and that the physical interaction be-
tween the two proteins significantly influences the re-
sponse to apoptotic stimuli.
Mode 2 is required for T-cell development
Having established a role for mode 2 regulation of apopto-
sis in response to exogenous apoptotic stimuli, we next
examined the requirement for mode 2 in vivo. Given the
critical importance of Bcl-xL in thymic T-cell develop-
ment (Ma et al. 1995; Motoyama et al. 1995), we analyzed
thymi of BakQ75L mutants. All major T-cell subtypes
were reduced by approximately threefold to fourfold in
BakQ75L/Q75L mice relative to wild-type mice, although
the loss of CD4+CD8+ double-positive thymocytes ac-
counted formost of this reduction (Fig. 4A). Upon compet-
itive bone marrow transplantation, the representation of
BakQ75L/Q75L cells was normal in hematopoietic progeni-
tor cells (Fig. 4B), whereas it was decreased in thymocytes
from the double-negative stage onwards (Fig. 4C). The rep-
resentation of mutant cells was not further decreased
within the splenic naïve T-cell compartments (Fig. 4D),
altogether suggesting that the BakQ75L mutation specifi-
cally compromises competitiveness in developing thymo-
cytes. Hence, the reduced thymic cellularity in BakQ75L
Figure 2. The BakQ75L mutation impairs heterodimerization
with Bcl-xL. (A) Relative binding affinities of wild-type Bak
BH3 or BakQ75L BH3 peptides for prosurvival proteins deter-
mined by competitive surface plasmon resonance binding as-
says. The Q75L mutation had the most significant effect on
Bcl-xL binding, similar to the equivalent mutation in hBAK
BH3. Data are presented as mean ± SD of n = 3 experiments.
(B) The effect of the Q75L mutation in full-length Bak on Bcl-
xL and Mcl-1 binding was assessed by coimmunoprecipitation.
Following treatment of MLM from wild-type, Bak+/Q75L, and
BakQ75L/Q75L mice with tBIDM97A, Mcl-1 coimmunoprecipi-
tated with Bak from all mitochondria. In contrast, only Bak
from Bak+/+ or Bak+/Q75L mitochondria, but not from
BakQ75L/Q75L mitochondria, bound to BCL-XL. tBIDM97A is a
mutant of tBID that retains the ability to activate Bax and
Bak but has a greatly reduced capacity to engage prosurvival
proteins compared with wild-type tBID (Supplemental Fig.
S1A), thereby eliminating any potential complications that
arise in these types of experiments when the BH3-only activator
can also inhibit the prosurvival protein:Bak interaction being
examined. (IP) Immunoprecipitation; (WCL) whole-cell lysate;
(WB) Western blot. (C ) The Q75L substitution did not affect
Bak homodimerization or association with VDAC2. Permeabi-
lized MEFs from Bak+/+, Bak+/Q75L, and BakQ75L/Q75L embryos
were untreated (−) or treated with tBID (+), and lysates were an-
alyzed by Blue Native PAGE. (D) The X-ray crystal structure of
hBAK (without its C-terminal hydrophobic tail) with the muta-
tion (Q77L; Protein Data Bank [PDB] ID 5FMI) equivalent to the
Q75L mutation in mBak overlayed with a previously published
structure of hBAK (PDB ID 2IMS). The overall structure of
BAKQ77L was not significantly affected by the mutation, and
the side chain of L77 is oriented identically to the wild-type
glutamine at this position on the solvent-exposed surface of
the α2 (BH3) helix. Human BAK is 78% identical to mBak,
and the Q77L mutation had an identical effect on hBAK BH3
binding to hBCL-XL. (E) Overlay of the crystal structures of
hBCL-XL bound (shown in gray) to wild-type hBAK BH3 (PDB ID
5FMK), mBakQ75L (PDB ID 5FMJ), or BIM BH3 (PDB ID 3FDL)
(Lee et al. 2009) peptides. All peptides bind similarly in the canon-
ical BH3 ligand-binding groove. (F ) In the wild-type hBAK BH3:
hBCL-XL complex, Q77 can potentially hydrogen-bond with
Y101 and/or Q111 on BCL-XL. (G) The crystal structure of BCL-
XL complexed with mBakBH3 Q75L, showing that this hydrogen
bond network is lost when Q75 is replaced with leucine, explain-
ing the reduced affinity for Bcl-xL. No electron density was appar-
ent for the side chain of Q111 in this complex structure.
Bcl-xL directly inhibits Bak in vivo
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mice is a T-cell-intrinsic defect, consistent with reduced
restraint of Bak by Bcl-xL.
Mode 2 regulates the homeostatic turnover
of platelets in vivo
It is well documented that Bcl-2 prosurvival proteins gov-
ern platelet survival. The critical regulator of viability in
these cells is Bcl-xL. Genetic deletion or pharmacological
inhibition of Bcl-xL causes severe thrombocytopenia due
to reduced platelet life span or induction of apoptosis, re-
spectively (Mason et al. 2007; Zhang et al. 2007; Kodama
et al. 2010; Wilson et al. 2010). The main effector of plate-
let apoptosis is Bak, as deletion of Bak causes thrombocy-
themia (an increase in platelet count) due to an almost
doubling of circulating platelet life span (Mason et al.
2007; Josefsson et al. 2011). If mode 2 were operative in
platelets, our data suggested that any reduction in the ca-
pacity of Bcl-xL to physically restrain Bak would lead to
premature platelet cell death. In agreement with this pre-
diction,Bak+/Q75L andBakQ75L/Q75Lmice displayed plate-
let counts fivefold to 10-fold lower than wild-type
counterparts (Fig. 5A). Platelet life span was dramatically
decreased, with t1/2 reduced from ∼5 d in wild-type ani-
mals to <5 h in Bak+/Q75L littermates and ∼2.5 h in
BakQ75L/Q75L (Fig. 5B). Consistent with the changes in
platelet survival being responsible for the thrombocytope-
nia, no reduction in megakaryocytes (platelet cell precur-
sors) was observed in the mutants. Indeed, mature
megakaryocyte numbers were elevated in Bak+/Q75L and
BakQ75L/Q75L mice (Fig. 5C), presumably a response to
thrombocytopenia.
We next examined the role of Bax. Loss of oneBax allele
had no impact on the thrombocytopenia in Bak+/Q75L
mice; however, platelet numbers increased significantly
when Bax was fully deleted (Fig. 5D). Bax deletion had
no effect in Bak+/+ mice, as previously reported (Mason
et al. 2007). This indicates that Bax contributes to platelet
cell death when Bak is not inhibited by Bcl-xL. In contrast,
deletion of Bim, a BH3-only protein that can both func-
tionally neutralize Bcl-xL and directly activate Bax and
Bak, had no effect on platelet numbers in Bak+/Q75L ani-
mals (Fig. 5E), althoughBim−/−mice had reduced platelets
compared with wild-type animals, consistent with previ-
ous reports (Bouillet et al. 1999). Hence, Bim is redundant
for Bak and Bax activation in platelets and likely does not
affect the ability of Bcl-xL to restrain either effector mole-
cule. Given that Bax contributes to platelet death when
Bak is not restrained by Bcl-xL, these data could suggest
that Bak itself is a Bax activator, possibly via a “feed-for-
ward” mechanism, as recently proposed (Chen et al.
2015). We therefore tested whether a BakQ75L BH3 peptide
could activate purified recombinant BAX and found that it
efficiently converted BAX to a dimer (Supplemental Fig.
S2). Hence, in platelets, Bax can potentially be activated
by unrestrained, activated Bak.
Discussion
Genetic studies have proven invaluable in establishing
which of the Bcl-2 family members regulate the life and
death of various tissues and cell types (Youle and Strasser
2008); however, they have not provided unambiguous
Figure 3. The Bak Q75L mutation renders cells more sensitive
to apoptotic stimuli. (A) The killing activity of BH3-only proteins
BIMS (promiscuous prosurvival protein binder) andNOXA (MCL-
1-selective) expressed retrovirally inMEFs. The BakQ75L renders
MEFs sensitive to Mcl-1 antagonism. (B) Mitochondria from per-
meabilized BakQ75L/Q75L MEFs have a lower threshold for cyto-
chrome c release than mitochondria from wild-type cells. An
approximately fourfold lower concentration of tBIDM97A in-
duced cytochrome c release from pellet (P) containing mitochon-
dria to soluble (S) fractions inBakQ75L/Q75L comparedwithBak+/+
MEFs. (C ) Mitochondria from BakQ75L/Q75L MEFs require a high-
er (approximately fourfold) concentration of full-length BCL-XL
to inhibit cytochrome c release in response to tBIDM97A (9
nM) treatment. (D–G) MEFs were treated with bortezomib (pro-
teasome inhibitor) (D), actinomycin D (transcription inhibitor)
(E), etoposide (topoisomerase inhibitor) (F), or cycloheximide
(translation inhibitor) (G) for 24 h prior tomeasurement of cell vi-
ability by FACS following propidium iodide staining. The percent
viability is the PI−ve population in treated cells relative to the
same population in cells treated with vehicle (DMSO). Data in
A and D–F are presented as mean ± SD of n = 3–4 experiments.
Lee et al.
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insight into the mechanisms underlying apoptosis regula-
tion in vivo. Such ambiguities arise because most genetic
manipulations disrupt both mode 1 and mode 2 cell death
regulation. Deleting a prosurvival protein prevents it from
sequestering BH3-only proteins (mode 1) and inhibiting
Bak and/or Bax (mode 2). A similar scenario arises with
knockout studies involving BH3-only family members.
For example, recent data from Bim/Bid/Puma/Noxa qua-
druple-knockout mice provided evidence that activator
BH3-only proteins (mode 1) are required for developmen-
tal cell death (e.g., removal of interdigital webbing). How-
ever, these BH3-only proteins also antagonize mode 2
Figure 5. Bcl-xL restrains Bak to inhibit
platelet death. (A) Bak+/Q75L and BakQ75L/
Q75Lmice had significantly decreased plate-
let numbers compared with Bak+/+ mice. n
= 20. (B) Platelets harboring theQ75Lmuta-
tion have a reduced life span. n = 8 for
BakQ75L/Q75L; n = 4 for Bak+/Q75L. t1/2 is in-
dicated by a dotted line. Platelets from
wild-type mice have a t1/2 of ∼5 d. n = 4.
(C ) The effect of the Q75L mutation on
platelet numbers is not due to impaired
megakaryopoiesis, as the number ofmature
megakaryocytes was elevated in bothBak+/
Q75L and BakQ75L/Q75Lmice compared with
wild-type mice. n = 12. (D) Loss of Bax re-
sulted in increased platelet counts in
Bak+/Q75L and BakQ75L/Q75L mice. n = 3–8.
(E) Loss of Bim has no effect on platelet lev-
els in platelets harboring the Q75L muta-
tion (n = 4–17), although loss of Bim alone
resulted in thrombocytopaenenia, as previ-
ously observed. Data are presented asmean
± SEM. (∗∗∗∗) P < 0.0001; (∗∗) P < 0.01; (∗) P <
0.05, Student’s unpaired t-test.
Figure 4. Loss of Bak restraint by Bcl-xL
causes reduced T-cell survival in vivo. (A)
Thymus cellularity is reduced by approxi-
mately threefold in BakQ75L/Q75L mice (n
= 15) compared with Bak+/+ mice (n = 11).
(B) Thymocyte defects were not due to de-
fects in lineage-negative (Lin−)/stem cell
antigen 1-positive (Sca1+)/Kit+ (LSK) pro-
genitor cells, as these were not affected by
the Q75L mutation. (C ) BakQ75L/Q75L thy-
mic T cells were underrepresented com-
pared with Bak+/+ T cells in competitive
bone marrow transplantation experiments.
n = 6. (D) The representation of BakQ75L/
Q75L cells in splenic CD44low CD62L+ naïve
T cells was similar to that of the thymic
compartment. Data are presented as mean
± SEM. (∗∗∗∗) P < 0.0001; (∗∗) P < 0.01, Stu-
dent’s unpaired t-test.
Bcl-xL directly inhibits Bak in vivo
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interactions; hence, it remains unclear whether one or
both of these mechanisms is at play.
The identification of the BakQ75L mutation allowed us
to clarify this situation, as it disrupts a mode 2 interaction
(specifically, the physical restraint of Bak by Bcl-xL) with-
out impairing either mode 1 interactions or Bak’s killing
activity. Indeed, the BakQ75L mouse essentially acts as
an in vivo reporter of cellular dependence on the Bak:
Bcl-xL interaction. Even at steady state, it is clear that pri-
mary cells in vivo rely on the physical restraint of Bak by
Bcl-xL to survive. Specifically, mode 2 regulation is criti-
cal for T-cell development, although previous in vitro
studies have shown a role for mode 1, with Bcl-xL inhibit-
ing T-cell apoptosis via engagement of Bim (Liu et al.
2006). Mode 2 is also critical for platelet life span. Plate-
lets circulate in the bloodstream until they encounter
one of two fates: consumption by hemostatic processes
(i.e., blood clotting) or apoptotic clearance. The latter is
mediated by Bak (Mason et al. 2007). In BakQ75L mice,
our data indicate that Bcl-xL is unable to restrain Bak
for the normal duration of platelet circulation. Premature
entry into apoptosis shortens platelet life span, leading
to thrombocytopenia. The partial rescue of platelet
counts in BakQ75L mice following Bax deletion demon-
strates that Bax contributes to platelet death once Bcl-xL
and Bak become disengaged. Whether this is via a
feed-forward activation mechanism (similar to that pro-
posed based on in vitro studies) (Llambi et al. 2011;
Chen et al. 2015; Dai et al. 2015) will require further
investigation.
Despite their hematopoietic defects, Bak+/Q75L and
BakQ75L/Q75L mice appear outwardly healthy to at least
6 mo of age. This supports the view that the Q75L muta-
tion influences only interaction with Bcl-xL and not other
prosurvival proteins, as the mutant mouse phenotype
would be more severe, as seen in Mcl-1-deficient (or
Bcl-2-deficient)mice. For example,mature B-cell numbers
do not change significantly in BakQ75L/Q75L mice
(Supplemental Fig. S3), although these are profoundly af-
fected by Mcl-1 or Bcl-2 deficiency. Hence, restraint of
Bak by other prosurvival proteins is sufficient to prevent
Bak-mediated apoptosis in most tissues. The most likely
candidate is Mcl-1, which, like Bcl-xL, engages Bak BH3
with high affinity and is widely expressed. Our MEF
data provide strong support of this proposition, as BakQ75L
cells more readily succumb to apoptotic triggers that have
an impact onMcl-1 functionality (e.g., Noxa induction via
etoposide and bortezomib) or levels (e.g., cycloheximide
treatment).
Our in vitro studies demonstrate a direct (inverse) corre-
lation between Bak:Bcl-xL affinity and a drug’s killing ac-
tivity, demonstrating that the strength of the mode 2
interaction sets the threshold for drug-induced apoptosis.
This is consistent with recent reports showing that acti-
vated BAK levels (or BAK:prosurvival protein complexes)
dictate chemosensitivity (Dai et al. 2015) and that mode
2 is more efficient than mode 1 at inhibiting apoptosis
(Llambi et al. 2011). Although previous studies implicated
prosurvival protein “priming” by BH3-only proteins as a
key determinant of drug sensitivity (Certo et al. 2006;
Vo et al. 2012), these new data argue that the strength of
mode 2 interactions (which varies widely for prosur-
vival:Bax/Bak protein pairs) is also important.
In summary, the BakQ75L mice provide the first in vivo
evidence of the physiological importance of mode 2 regu-




Recombinant human and mouse Bcl-2 prosurvival proteins with
N-terminal and/or C-terminal truncations for binding studies (h/
mBCL-2ΔC22, h/mBCL-XLΔC24, mBcl-xLY101FΔC24, mBcl-xL
Q111AΔC24, mBcl-xLY101F/Q111AΔC24, h/mBCL-W C29S/
A128EΔC29, h/mMCL-1ΔN170ΔC23, and h/mBFL-1ΔC19);
the loop-deleted form of hBCL-XL (ΔN27–82ΔC24) and
hBAKΔN22ΔC25Q77L used for crystallization; and full-length
hBCL-XL, htBID, hBAXΔC21, and htBIDM97Aused in other stud-
ies were all expressed and purified exactly as described previously
(Kluck et al. 1999; Chen et al. 2005; Moldoveanu et al. 2006; Lee
et al. 2007, 2008; Czabotar et al. 2013; Hockings et al. 2015).
Synthetic peptides
Synthetic peptides were synthesized by Mimotopes and purified
by reverse-phase high-performance liquid chromatography
(HPLC) to ≥90%purity. The peptides used in this study were
hBAK BH3 (LPLQPSSTMGQVGRQLAIIGDDINRRYDSEFQT
M), mBak BH3 (LPLEPNSILGQVGRQLALIGDDINRRYDTEFQ
NL), mBak Q75L BH3 (LPLEPNSILGQVGRLLALIGDDINRRYD
TEFQNL), BIM BH3 (DMRPEIWIAQELRRIGDEFNAYYARR),
BAD BH3 (NLWAAQRYGRELRRMSDEFVDSFKKG), and BID
M97A BH3 (SQEDIIRNIARHLAQVGDSADRSIPPG).
Phage display binding studies
A 26-amino-acid residue peptide encompassing the Flag-tagged
BAK BH3 domain plus flanking residues (PSSTMGQVGRQ
LAIIGDDINRRYDSE) was fused via a linker sequence (GGGT)
to theN terminus of theM13 phage gene3 in the phagemid vector
described previously (Fairlie et al. 2003). Alanine-scanning con-
structs and phage particles were isolated from cell supernatants
and tested in phage competition ELISAs as described previously
(Lee et al. 2008).
Surface plasmon resonance competitive binding assays
Solution competition assays were performed by using a Biacore
3000 instrument (GE Healthcare) as described previously (Lee
et al. 2009). In brief, recombinant, 10 nM purified human or
mouse prosurvival proteins was incubated with varying concen-
trations of peptide for at least 2 h in running buffer (10 mM
HEPES at pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% [v/v]
Tween20) prior to injection onto a CM5 sensor chip on which ei-
ther wild-type BIM BH3 or an inert BIM BH3 mutant peptide
(BIM4E) was immobilized. Specific binding of the prosurvival
protein to the surface in the presence and absence of competitor
peptides was quantified by subtracting the signal obtained on the
BIM mutant channel from that obtained on the wild-type BIM
channel.
Lee et al.
1246 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 15, 2020 - Published by genesdev.cshlp.orgDownloaded from 
Cell lines
The Bak+/+, Bak+/Q75L, and BakQ75L/Q75L MEFs were generated
from embryonic day 13.5–14 embryos and immortalized (at pas-
sage 2–4) with SV40 large T antigen. To generate cell lines ex-
pressing BAK mutants, MEFs were transduced with retroviruses
in which expression of each protein was linked to GFP expression
or a hygromycin resistance gene via an internal ribosome entry
site sequence in pMIG or pMIH vectors. Following infection,
GFP+ve cells (generated from pMIG retroviruses) were sorted,
while cells infected with pMIH retroviruses were selected by
growing them in 250 μg/mL hygromycin. Cells were maintained
in DME KELSO medium supplemented with 10% (v/v) fetal bo-
vine serum, 250 μML-asparagine, and 50 μM 2-mercaptoethanol.
Cell-killing assays
For long-term clonogenic survival assays, MEFs were transduced
with the indicated constructs in which expression of each protein
was linked to GFP or mCherry expression via an internal ribo-
some entry site sequence.GFP+ve or GFP+ve plusmCherry+ve cells
(in cases where the effect of gene coexpression was examined)
were then sorted and plated at 150 cells per well in six-well plates
and incubated for 7 d. Colonies were then stained with Coomas-
sie blue and counted. Short-term killing assays were performed
on cells treated with various drugs (etoposide, bortezomib, acti-
nomycin D, and cycloheximide). Twenty-four hours after treat-
ment, cells were stained with 5 μg/mL propidium idodide and
then analyzed by FACS (FACSCalibur, BD Biosciences). Cell via-
bility was determined by establishing the fraction of PI−ve cells
relative to the same population in cells treated with vehicle
(DMSO) alone.
Mutagenesis screen and isolation of the BakQ75L mutation
Male BALB/cmicewere injected intraperitoneally with 85mg/kg
ENU (Sigma-Aldrich) weekly for 3 wk. Twelve weeks after the
last cycle, mice were mated with untreated BALB/c females to
produce first-generation (G1) progeny. Peripheral blood from
these animals was taken at 7 wk of age, and blood cell counts
were analyzed using an ADVIA 2120 hematology analyzer (Sie-
mens). Mice with low platelet counts were rebled at 9 wk of age
to confirm a stable phenotype and then crossed to C57BL/6.
Thrombocytopenic F1 offspring were back-crossed to C57BL/6
to generate F1N1 offspring. Twenty-one affected F1N1 mice
were genotyped for 660 SNPs spaced at 5- to 10-Mb intervals
throughout the genome using the iPLEX Gold method, the Mas-
sARRAY system (Sequenom), and anAutoflexMALDI-TOFmass
spectrometer (Bruker) at the Australian Genome Research Facil-
ity (AGRF). Haplotypes were constructed, and regions of hetero-
zygosity were identified using Excel version 14.3.4 software
(Microsoft). Additional F1N1micewere genotyped formore finely
spaced SNPs using the Amplifluor SNP HT genotyping system
FAM-JOE (Merck Millipore). Results were visualized, and geno-
types were assigned using assayauditorEP.xls (Merck Millipore)
and Excel version 14.3.4 software (Microsoft). The causative le-
sion was mapped to a 4.5-Mb region between rs13482920 and
rs13482937 on chromosome 17. Candidate genes were sequenced
by Sanger sequencing at the AGRF. Experimental mice were
backcrossed onto C57BL/6 background for >10 generations prior
to crossing onto Bax−/− and Bim−/− strains. All animal experi-
ments complied with the regulatory standards of and were ap-
proved by the Walter and Eliza Hall Institute Animal Ethics
Committee.
In vivo assessment of platelet life span
Mice were injected intravenously with the fluorescently labeled
rat anti-GPIbβ X488 antibody (Emfret) at 0.15 µg per gram of
body weight. Platelet life span was measured by flow cytometry
as previously described (Josefsson et al. 2012). Mice were bled
from the tail vein every 2.5 h, and platelets were identified in
platelet-rich plasma as being CD41+, with the proportion of
X488+ remaining cells assessed at each time point.
Competitive bone marrow transfer experiments
Mixed bone marrow chimeras were generated by transplanting a
1:3 ratio of Ly5.1+ competitor cells and Ly5.2+ test cells (5 × 106
total bone marrow cells) into lethally irradiated (1100 rad)
Ly5.1+ Ly5.2+ recipients. Test bone marrow cells were isolated
from wild-type, Bak+/Q75L, or BakQ75L/Q75L mice. Bone marrow
chimeras were analyzed 12 wk after reconstitution by flow cy-
tometry performed with a Fortessa (BD Biosciences), and data
were analyzed using FlowJo software (Tree Star). Monoclonal an-
tibodies were produced at the Walter and Eliza Hall Institute un-
less otherwise indicated and labeled in-house with fluorescein
isothiocyanate, R-phycoerythrin, R-phycoerythrin-Cy7, allophy-
cocyanin, Alexa700, or biotin. Clone numberswereCD4 (GK1.5),
CD8 (53.6.7), CD19 (1D3), CD44 (IM7), CD45.1 (A20), CD45.2
(S450-15-2), TER119 (Ly76), GR1 (RB6-8C5), CD11b (M1/70),
Sca1 (D7), Kit (ACK4), and B220 (RA3-6B2). CD62L-allophyco-
cyanin was purchased from eBioscience. Streptavidin PE-Texas
red was purchased from Life Technologies. Fluoro-Gold (Sigma)
was used to exclude dead cells.
Hemopoietic analysis
Single-cell suspensions were prepared from the spleen and thy-
mus, and viable leukocytes from 60 d-old mice were determined
with a CASY cell counter (Scharfe System GmbH). Blood cell
counts were determined using an ADVIA 2120 hematology ana-
lyzer (Siemens) and then depleted of red cells by treatment with
0.168 M ammonium chloride before FACS analysis. The compo-
sition of leukocyte populations was determined by flow cytomet-
ric analysis on a FASCalibur (BD Biosciences) following staining
with fluorochrome-labeled surface marker-specific monoclonal
antibodies, and data were analyzed using FlowJo version 9.3.2
(TreeStar). Themonoclonal antibodieswere produced and labeled
with fluorescein isothiocyanate, R-phycoerythrin, or allophyco-
cyanin at the Walter and Eliza Hall Institute unless otherwise in-
dicated. Antibody clone numbers were CD4 (YTA3.2.1), CD8
(YTS169), THY-1 (T24.3.21), IgM (5.1), IgD (11-26C), B220 (RA3-
6B2), c-Kit (ACK-4), GR-1 (RB6-8C5), MAC-1 (MI/70), CD3
(145-2C11), and B220 (RA3-6B2).
Cytochrome c release assay
MEFs were permeabilized in digitonin containing buffer (20 mM
HEPES at pH 7.2, 100mMKCl, 5mMMgCl2, 1mMEDTA, 1mM
EGTA, 1250 mM sucrose, 0.05% [w/v] digitonin) and incubated
with tBIDM97A for 1 h at 30°C before pelleting via centrifuga-
tion. The supernatant was retained (soluble fraction), and the pel-
let was lysed in TritonX-100-containing buffer (20mMTris at pH
7.4, 135 mMNaCl, 1.5 mMMgCl2, 1 mM EDTA, 10% [v/v] glyc-
erol, 1% [v/v] Triton X-100, protease inhibitors) to generate the
pellet fraction. In experiments examining BCL-XL inhibition of
cytochrome c release, various concentrations of recombinant
full-length hBCL-XL were added immediately prior to the addi-
tion of 9 nM tBIDM97A. Both soluble and pellet fractions were
Bcl-xL directly inhibits Bak in vivo
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analyzed for cytochrome c by Western blotting using an anti-cy-
tochrome c antibody (BD Biosciences, clone 7H8.2C12).
Blue Native PAGE of BAK oligomerization
Membrane fractions from MEFs (wild-type, Bak+/Q75L, BakQ75L/
Q75L, or Bax−/−/Bak−/− reconstituted with BAK mutants) were
generated by permeabilizing cells with 0.025% (w/v) digitonin
in permeabilization buffer (20 mM HEPES/KOH at pH 7.5, 100
mM sucrose, 2.5 mM MgCl2, 50 mM KCl supplemented with
Complete protease inhibitors [Roche], 2 mM DTT). Membrane
fractions were then treated for 30 min at 30°C in the presence
or absence of recombinant tBID prior to solubilization in 20
mM Bis-tris (pH 7.4), 50 mM NaCl, 10% (v/v) glycerol, 2 mM
DTT, and 1% (w/v) digitonin. Insoluble debris was removed by
centrifugation at 13,000g, and 10× BN-PAGE loading dye (5%
[w/v] Coomassie blue G-250 [Bio-Rad] in 500 mM 6-aminohexa-
noic acid, 100 mM Bis-tris at pH 7.0) was then added. Samples
were electrophoresed on 4%–13% native gels in anode buffer
(50 mM Bis-tris at pH 7.0) and blue cathode buffer (50 mM Tri-
cine, 15mMBis-tris unbuffered containing 0.02% [w/v] Coomas-
sie blue G-250), with blue cathode buffer replaced with clear
buffer (without Coomassie blue) when the dye front was one-
third through the resolving gel. Gels were transferred to PVDF
and immunoblotted for BAK (7D10).
Immunoprecipitation assays
MLMwere prepared as described (Uren et al. 2005).MLMwere di-
luted to 1 mg/mL in MELB (100 mM KCl, 2.5 mM MgCl2, 100
mM sucrose, 20 mMHEPES/KOH at pH 7.5, 5 mMDTT) supple-
mented with protease inhibitor cocktail, 4 mg/mL pepstatin A,
and 5 mM DTT. Full-length human BCL-XL or mouse Mcl-
1ΔN170ΔC23 (both at 32 nM) was preincubated with MLM for
20 min at 37°C before addition of 30 nM tBIDM97A as indicated
and incubation for a further 2 h at 37°C. Samples were solubilized
with 1% (w/v) digitonin and immunoprecipitated as described
(Dewson et al. 2008) using anti-BCL-XL IC2 rat (Willis et al.
2005) or anti-Mcl-1 14C11 rat (Banerjee et al. 2008) monoclonal
antibodies.
Protein crystallization
The BAK BH3:BCL-XL and BakQ75L BH3:BCL-XL peptide com-
plexes used a “loop-deleted” form of human BCL-XL (Δ27–82
and, without membrane anchor, residues 210–233), which forms
an α1 domain-swapped dimer yet retains BH3 domain-binding ac-
tivity (Lee et al. 2007). Crystals were obtained by mixing BCL-XL
with the BH3 peptides at a molar ratio of 1:1.3 and then concen-
trating the sample to 10 mg/mL. Crystallization trials were per-
formed at the Bio21 Collaborative Crystallisation Centre. BAK
BH3:BCL-XL complex crystals were grown by the sitting drop
method at room temperature in 0.16 M calcium acetate, 0.08 M
sodium cacodylate (pH 6.5), 20% (v/v) glycerol, 14.4% (w/v)
PEG 8000, and, for the BCL-XL:BakQ75L BH3 complex, in
0.2 M sodium thiocyanate and 20% (w/v) PEG 3350.
BAKΔN22ΔC25Q77L crystals were grown in 10% (w/v) PEG
3350, 0.1 M sodium acetate (pH 4.5), and 20 mM zinc acetate,
similar to the conditions previously reported for wild-type BAK
(Moldoveanu et al. 2006). Prior to cryocooling in liquid N2,
BakQ75L BH3:BCL-XL and BAKΔN22ΔC25Q77L crystals were
equilibrated into cryoprotectant consisting of reservoir solution
containing 15% (v/v) ethylene glycol. Crystals were mounted
directly from the drop and plunge-cooled in liquid N2.
Crystal diffraction data collection and structure determination
Diffraction data were collected at 100 K at the Australian Syn-
chrotronMX1 andMX2 beamlines (wave-length for all structures
was 0.95364 Å). The diffraction data were integrated and scaled
with either HKL2000 (Otwinowski and Minor 1997) for the
BAK BH3:BCL-XL structure or XDS (Kabsch 2010) for the
BAKQ75L BH3:BCL-XL and full-length BAKQ77L structures.
The structures were solved by molecular replacement with
Phaser (McCoy et al. 2005) using the previous crystal structures
of BCL-XL from the BECLIN BH3:BCL-XL complex (Protein
Data Bank [PDB] ID 2P1L) (Oberstein et al. 2007) with the
BECLIN BH3 peptide removed for the BCL-XL peptide complex
structures or the wild-type BAK (PDB ID 2IMS) for the BAKQ77L
structure as searchmodels.Multiple rounds of building in COOT
(Emsley and Cowtan 2004) and refinement in PHENIX (Kabsch
2010) led to the final models.
BAX dimerization assay
The dimerization of BAX treated with BH3 peptides was per-
formed as described previously (Czabotar et al. 2013). Briefly, re-
combinant BAXΔC21 was incubated with threefold molar excess
of each peptide in Tris-buffered saline (pH 8.0) containing 1.0%
(w/v) CHAPS. Dimerization was assessed by gel filtration chro-
matography on a Superdex 75 10/300 column.
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